newsfilter
← Latest News
Business Wire·

iECURE Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ECUR-506 for Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency

Reached alignment with FDA on endpoints, comparators and sample size for the ongoing OTC-HOPE study which could support Biologics License Application (BLA) Awarded Innovation Passport under the United Kingdom's